Episcleral infantile hemangioma successfully treated with topical timolol

Blanco, C. Ciudad; Domínguez, Minia Campos; García, Basilio Moreno; Álvarez-Santullano, Cándida Ana Villanueva; Fröhner, B. Berenguer; Fernández, Rafael Ramos

doi:10.1111/dth.12173

Cited by 9 publications

(7 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In all treated subjects, beta‐blockers led to partial or complete clearance of IH, usually within a few months of treatment. This is in line with recent case reports describing excellent response of conjunctival IH to systemic and topical beta‐blocker treatment . Complete or near‐complete response occurred in 18% of our subjects, which is significantly less than is our general experience with beta‐blocker treatment of cutaneous IH and data in the recent literature as well .…”

Section: Discussionsupporting

confidence: 91%

Infantile hemangiomas with conjunctival involvement: An underreported occurrence

Theiler

Baselga

Gerth‐Kahlert

et al. 2017

Pediatric Dermatology

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 91%

Infantile hemangiomas with conjunctival involvement: An underreported occurrence

Theiler

Baselga

Gerth‐Kahlert

et al. 2017

Pediatric Dermatology

View full text Add to dashboard Cite

show abstract

“…A case of a rare episcleral hemangioma treated with timolol maleate 0.5% twice a day also regressed completely after 5 months of treatment without rebound growth a year after discontinuing the medication. 29 It is important to note that in the authors' experience, superficial periocular IH are more likely to respond to topical therapy than deeper lesions, but some deeper lesions may show adequate response as well. [50][51] In certain cases without immediate amblyopia risk, it is therefore reasonable to initiate a trial of topical timolol first prior to escalating to oral therapy.…”

Section: Topical Beta Blockersmentioning

confidence: 74%

“…[17][18][19][20][21][22][23][24][25][26] More recently, several case series have also evaluated topical beta blocker therapy with timolol for periocular IH with promising results. [27][28][29][30][31] Herein, we summarize the literature and treatment recommendations for the use of oral and topical beta blockers in periocular IH.…”

Section: Introductionmentioning

confidence: 99%

Beta Blockers in the Treatment of Periocular Infantile Hemangiomas: A Review

Tran

Choi

Wester

2016

IMR

View full text Add to dashboard Cite

Infantile hemangiomas (IH) are the most common benign tumor of infancy, and in the periocular region can be associated with permanent visual impairment from amblyopia. Previous treatment options included systemic and local corticosteroids, surgical excision, laser therapy, and in rare cases immunomodulatory therapy, many of which had variable outcomes with undesirable side effect profiles. Since their initial use for IH in 2008, beta blockers have become the mainstay of therapy for periocular IH due to their excellent clinical efficacy and tolerability. While the exact mechanism of action of beta blockers in IH has not been fully elucidated, both oral and topical therapy have demonstrated low rates of adverse events and improved outcomes in the management of periocular IH. This review summarizes the most recent studies on the clinical outcomes, management, and guidelines for the treatment of periocular IH with topical and oral beta blockers.

show abstract

“… 13 However, systemic propranolol with a dose of two mg/kg/day is additionally used but can cause adverse systemic side effects. 14 , 15 …”

Section: Introductionmentioning

confidence: 99%

Role of topical beta blockers in regression of infantile capillary hemangioma

Junejo

Rebecca²,

Memon³

et al. 2021

Pak J Med Sci

View full text Add to dashboard Cite

Objective: To observe efficacy of Timolol maleate 0.5% by topical and surface application in infantile superficial capillary hemangioma of eyelid. Methods: This multi-centered clinical case series was carried out at Ophthalmology Department of Bilawal Medical College and Institute of Ophthalmology, LUMHS, Jamshoro from November 2019 to May 2020. We included 14 subjects. All the patients were subjected to detailed clinical examination. Before starting the topical beta blockers, the enrolled subjects had obtained the expert opinion by pediatrician to rule out any preexisting developmental cardio vascular disease. Topical beta blockers 0.5% drops were thus started with, against the ongoing finding of superficial capillary hemangioma of eyelid. Results: There was significant regression in size of infantile hemangioma after treating with topical timolol maleate 0.5%. We included 14 subjects in this study. Mean±SD age of patients was 4.94. Complete regression was seen in 08 subjects at the end of 12 weeks (64%) while 03 were completely cured at 08 weeks (21%) and 01 patient lost follow up with us. No significant ocular and systemic side effects were noted. Conclusion: Topical timolol maleate 0.5% can be the first-line treatment modality for superficial capillary hemangiomas due to its better safety and efficacy. doi: https://doi.org/10.12669/pjms.37.7.4317 How to cite this:Junejo MS, Rebecca, Memon MN, Shaikh SP. Role of topical beta blockers in regression of infantile capillary hemangioma. Pak J Med Sci. 2021;37(7):---------. doi: https://doi.org/10.12669/pjms.37.7.4317 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

show abstract

Episcleral infantile hemangioma successfully treated with topical timolol

Cited by 9 publications

References 14 publications

Infantile hemangiomas with conjunctival involvement: An underreported occurrence

Infantile hemangiomas with conjunctival involvement: An underreported occurrence

Beta Blockers in the Treatment of Periocular Infantile Hemangiomas: A Review

Role of topical beta blockers in regression of infantile capillary hemangioma

Contact Info

Product

Resources

About